1. Home
  2. RVLV vs MIRM Comparison

RVLV vs MIRM Comparison

Compare RVLV & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVLV
  • MIRM
  • Stock Information
  • Founded
  • RVLV 2003
  • MIRM 2018
  • Country
  • RVLV United States
  • MIRM United States
  • Employees
  • RVLV N/A
  • MIRM N/A
  • Industry
  • RVLV Catalog/Specialty Distribution
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVLV Consumer Discretionary
  • MIRM Health Care
  • Exchange
  • RVLV Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • RVLV 1.4B
  • MIRM 3.3B
  • IPO Year
  • RVLV 2019
  • MIRM 2019
  • Fundamental
  • Price
  • RVLV $24.34
  • MIRM $73.00
  • Analyst Decision
  • RVLV Buy
  • MIRM Strong Buy
  • Analyst Count
  • RVLV 14
  • MIRM 10
  • Target Price
  • RVLV $26.79
  • MIRM $74.20
  • AVG Volume (30 Days)
  • RVLV 1.0M
  • MIRM 679.0K
  • Earning Date
  • RVLV 11-04-2025
  • MIRM 11-11-2025
  • Dividend Yield
  • RVLV N/A
  • MIRM N/A
  • EPS Growth
  • RVLV 38.54
  • MIRM N/A
  • EPS
  • RVLV 0.63
  • MIRM N/A
  • Revenue
  • RVLV $1,182,554,000.00
  • MIRM $429,161,000.00
  • Revenue This Year
  • RVLV $9.12
  • MIRM $53.08
  • Revenue Next Year
  • RVLV $6.65
  • MIRM $20.45
  • P/E Ratio
  • RVLV $37.80
  • MIRM N/A
  • Revenue Growth
  • RVLV 10.68
  • MIRM 62.33
  • 52 Week Low
  • RVLV $16.80
  • MIRM $36.86
  • 52 Week High
  • RVLV $39.58
  • MIRM $78.10
  • Technical
  • Relative Strength Index (RSI)
  • RVLV 62.09
  • MIRM 57.67
  • Support Level
  • RVLV $22.31
  • MIRM $73.35
  • Resistance Level
  • RVLV $24.01
  • MIRM $74.99
  • Average True Range (ATR)
  • RVLV 0.90
  • MIRM 2.34
  • MACD
  • RVLV 0.08
  • MIRM -1.01
  • Stochastic Oscillator
  • RVLV 95.49
  • MIRM 16.75

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: